On June 8, AstraZeneca’s oral GLP-1 receptor agonist, elecoglipron, is advancing to a Phase III clinical program following positive results from the VISTA and SOLSTICE Phase IIb trials.
AstraZeneca (NYSE:AZN) noted that the Phase II data will help optimize the dose escalation schedule for the upcoming Phase III studies, which are designed to further enhance tolerability for patients.
AstraZeneca (AZN) Advances Oral GLP-1 Receptor Agonist Elecoglipron to Phase III TrialsPixabay/Public DomainThe expanded Phase III program includes the EMBOLD and ELUMINATE trials, which will evaluate elecoglipron as both a monotherapy and in combination with other treatments.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
AstraZeneca (NYSE:AZN) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 8, AstraZeneca’s oral GLP-1 receptor agonist, elecoglipron, is advancing to a Phase III clinical program following positive results from the VISTA and SOLSTICE Phase IIb trials. In the VISTA study, adults with obesity or overweight achieved 11.8% weight loss at 36 weeks, while the SOLSTICE trial showed a 1.9% reduction in HbA1c for adults with type 2 diabetes at 26 weeks.
The safety profile for the drug was consistent with the GLP-1 class, with mostly mild to moderate gastrointestinal adverse events reported. AstraZeneca (NYSE:AZN) noted that the Phase II data will help optimize the dose escalation schedule for the upcoming Phase III studies, which are designed to further enhance tolerability for patients.
AstraZeneca (AZN) Advances Oral GLP-1 Receptor Agonist Elecoglipron to Phase III Trials
Pixabay/Public Domain
The expanded Phase III program includes the EMBOLD and ELUMINATE trials, which will evaluate elecoglipron as both a monotherapy and in combination with other treatments. These trials aim to address the complex nature of obesity and type 2 diabetes while investigating the drug’s long-term cardiovascular and kidney health outcomes.
AstraZeneca (NYSE:AZN) is a global biopharmaceutical company headquartered in Cambridge, focused on oncology. It develops a broad portfolio of cancer treatments targeting lung, breast, ovarian, and blood cancers, aiming to advance science-led therapies across multiple platforms.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
